Wiki · Profile

Semaglutide

Ozempic · Wegovy · Rybelsus

Metabolic & WeightApproved

MW: 4114g/mol
Formula: C187H291N45O59

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) derived from a naturally occurring hormone that plays a role in glucose metabolism and appetite regulation. Researchers primarily study semaglutide for its potential in managing obesity and type 2 diabetes. Key findings from clinical trials indicate that semaglutide can lead to significant weight loss and improvements in glycemic control, with participants experiencing an average weight reduction of approximately 13.7% over 72 weeks. Additionally, studies have shown that semaglutide has a favorable safety profile, with most adverse events being mild to moderate in severity. Current research continues to explore its efficacy in various populations and its long-term effects on health outcomes.

Chemical Profile

Chemical Structure

Formula	C187H291N45O59
Molecular Weight	4114 g/mol
CAS Number	910463-68-2
PubChem CID	56843331

Half-Life

SCSubcutaneous

~7 days

INIntranasal

Not applicable

POOral

Poor bioavailability

The long half-life supports once-weekly dosing for subcutaneous administration.

Mechanism

Mechanism of Action

Semaglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily activating GLP-1 receptors (GLP-1R) in pancreatic beta cells, which enhances insulin secretion in a glucose-dependent manner. This activation triggers the cAMP/PKA signaling pathway, leading to increased insulin gene expression and secretion, while also promoting satiety and reducing gastric emptying, thereby contributing to weight loss and improved glycemic control. The full extent of its mechanisms, particularly regarding long-term effects on weight regulation and potential impacts on other signaling pathways, remains to be fully elucidated.

Research

122 Research Publications

8,613

Total Citations

Human/RCT

9.1

Avg. Influence

2025

Latest

Sort

Filter

01Top

#01

Obesity Management in Adults: A Review.

ReviewInfluence27.0

698

The review highlighted that GLP-1 agonists, including semaglutide, can achieve significant weight loss and improve various obesity-related health outcomes in adults.

1.7 mgsubcutaneously(human)72 weeks2.4 mgsubcutaneously(human)72 weeks5 mgsubcutaneously(human)40 weeks10 mgsubcutaneously(human)40 weeks15 mgsubcutaneously(human)40 weeks1 mgsubcutaneously(human)40 weeks2.4 mgsubcutaneously(human)68 weeks0.5 mgsubcutaneous(human)30 weeks1.0 mgsubcutaneous(human)30 weeks14 mgoral(human)not mentioned

PubMed

02Top

#02

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.

Pratley Richard E, et al. · The lancet. Diabetes & endocrinology · 2018

HumanInfluence49.0

683

Researchers observed that semaglutide was superior to dulaglutide in improving glycemic control and reducing body weight in patients with type 2 diabetes.

Key findings

01Semaglutide was superior to dulaglutide in improving glycemic control.
02Patients using semaglutide experienced greater weight loss compared to those on dulaglutide.
03Both medications had a similar safety profile during the trial.

PubMed

03Top

#03

Advances in oral peptide therapeutics.

ReviewInfluence17.0

551

Researchers observed that advances in oral peptide therapeutics, including oral semaglutide, have improved adherence to treatment regimens for endocrine disorders.

PubMed

#04

Semaglutide lowers body weight in rodents via distributed neural pathways.

Gabery Sanaz, et al. · JCI insight · 2020

HumanInfluence33.0

549

Researchers found that semaglutide, a medication used for diabetes, can lower body weight in rodents by influencing brain pathways related to food intake and preference. The study observed that semaglutide activates specific brain areas without crossing the blood-brain barrier, leading to reduced food consumption without affecting energy expenditure.

Key findings

01Semaglutide modulated food preferences and reduced food intake in rodents.
02The medication accessed various brain regions involved in appetite control without crossing the blood-brain barrier.
03Activation of certain brain pathways suggests that semaglutide influences how meals are terminated.

PubMed

#05

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

Ahmann Andrew J, et al. · Diabetes care · 2018

HumanInfluence24.0

511

The study demonstrated that semaglutide significantly improved glycemic control and reduced body weight compared to exenatide ER in individuals with type 2 diabetes over 56 weeks.

Key findings

01Semaglutide was superior to exenatide in improving glycemic control after 56 weeks.
02Participants using semaglutide experienced greater weight loss compared to those using exenatide.
03Both medications had comparable safety profiles throughout the study.

PubMed

#06

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.

HumanInfluence31.0

367

The study demonstrated that semaglutide significantly reduced glycated hemoglobin and body weight compared to placebo when added to basal insulin in patients with uncontrolled type 2 diabetes.

PubMed

#07

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.

HumanInfluence19.0

344

The study demonstrated that semaglutide led to greater reductions in HbA1c and body weight compared to insulin glargine in insulin-naive patients with type 2 diabetes.

5 mgsubcutaneous(human)40 weeks10 mgsubcutaneous(human)40 weeks15 mgsubcutaneous(human)40 weeks1 mgsubcutaneous(human)40 weeks1.7 mgsubcutaneous(human)72 weeks2.4 mgsubcutaneous(human)72 weeks0.5 mgsubcutaneous(human)30 weeks1.0 mgsubcutaneous(human)30 weeks0.5 mgsubcutaneous(human)40 weeks1.0 mgsubcutaneous(human)40 weeks

PubMed

#08

Safety of Semaglutide.

Smits Mark M & Van Raalte Daniël H · Frontiers in endocrinology · 2021

ReviewInfluence20.0

318

Researchers observed that semaglutide primarily causes mild-to-moderate gastrointestinal disturbances and has a favorable safety profile similar to other GLP-1 receptor agonists.

Key findings

01Researchers observed that semaglutide primarily causes mild to moderate gastrointestinal disturbances.
02The review noted an increased risk of gallbladder disease, but no unexpected safety issues were identified.
03Researchers found that the safety profile of semaglutide is similar to other medications in its class, with careful monitoring recommended for certain patients.

PubMed

#09

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.

ReviewInfluence7.0

249

Researchers observed that next-generation therapies combining GLP-1 receptor agonists with other peptides may enhance efficacy in treating metabolic diseases compared to GLP-1 receptor agonists alone.

1 mgsubcutaneous(human)40 weeks2.4 mgsubcutaneous(human)72 weeks14 mgoral(human)varied0.5 mgsubcutaneous(human)30 weeks1.0 mgsubcutaneous(human)30 weeks2.4 mgsubcutaneous(human)32 weeks

PubMed

#10

Central and peripheral GLP-1 systems independently suppress eating.

AnimalInfluence18.0

235

Researchers observed that central and peripheral GLP-1 systems independently suppress eating in mice, suggesting potential for combined pharmacological strategies in obesity treatment.

PubMed

Safety

Safety & Handling

Research Gaps

The efficacy and safety of semaglutide in specific populations, such as those with obesity but without type 2 diabetes, remain unexamined in direct comparative trials against newer agents like tirzepatide. Additionally, the long-term effects of semaglutide on cardiovascular health and potential risks for pancreatic and thyroid cancers are still unclear due to insufficient data from extended follow-up studies.

Solubility

Semaglutide is soluble in water and exhibits limited solubility in organic solvents such as acetonitrile and DMSO.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

🇩🇪DE

Approved as a medicinal product for specific indications. Not a controlled substance.

🇺🇸US

Approved by the FDA for type 2 diabetes and weight management. Not a controlled substance.

🇦🇺AU

Approved by the TGA for type 2 diabetes and weight management.

🇬🇧UK

Approved by the MHRA for type 2 diabetes and weight management.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Publications per Year

50 total

Pricing

Price Comparison

BESTStrate LabsUS
10mg
$34.95
Price/mg
$3.50/mg
View
Polaris PeptidesUS
20mg
$165.00
Price/mg
$8.25/mg
View
Polaris PeptidesUS
12.5mg
$105.00
Price/mg
$8.40/mg
View
Polaris PeptidesUS
10mg
$90.00
Price/mg
$9.00/mg
View
Prime PeptidesUS
10mg
$90.00
Price/mg
$9.00/mg
View

Vendor	Amount	Price	Price/mg	Link
BESTStrate LabsUS	10mg	$34.95	$3.50/mg	View
Polaris PeptidesUS	20mg	$165.00	$8.25/mg	View
Polaris PeptidesUS	12.5mg	$105.00	$8.40/mg	View
Polaris PeptidesUS	10mg	$90.00	$9.00/mg	View
Prime PeptidesUS	10mg	$90.00	$9.00/mg	View

Top 5 of 24 offers from 11 vendors. Prices updated daily.

See all Semaglutide prices

Mechanism

Tools

Reconstitution Calculator

Calculate reconstitution volumes for Semaglutide

Serum Level Visualizer

Visualize Semaglutide serum levels over time

Mechanism

Related Peptides

AOD-9604 5-Amino-1MQ Tirzepatide Retatrutide Liraglutide Adipotide

Track Semaglutide in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp Store Get it onGoogle Play

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer